HB 3192
Appropriates moneys from the General Fund to the Oregon Health Authority for the purpose of screening newborns for five specific diseases under the Northwest Regional Newborn Bloodspot Screening Program.
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take actionPublic sentiment
Support
80%
Oppose
20%
- Introduced
- Passed House
- Passed Senate
- To Governor
- Became Law
Bill overview
This bill provides funding to the Oregon Health Authority to expand newborn screening for five specific genetic diseases. The money, sourced from the General Fund, will be used to screen newborns for Mucopolysaccharidosis type II, Guanidinoacetate methyltransferase deficiency, Krabbe disease, Duchenne muscular dystrophy, and Cytomegalovirus. This screening is part of the Northwest Regional Newborn Bloodspot Screening Program, aiming to identify these conditions early for potential treatment.
Key provisions
- Allocates $4,000,000 from the General Fund to the Oregon Health Authority.
- Funds screening newborns for Mucopolysaccharidosis type II (MPS II).
- Funds screening newborns for Guanidinoacetate methyltransferase deficiency (GAMT).
- Funds screening newborns for Krabbe disease.
- Funds screening newborns for Duchenne muscular dystrophy.
- Funds screening newborns for Cytomegalovirus.
Who is affected
- Newborn infants
- Oregon Health Authority
- Parents of newborns
- Healthcare providers
- Oregon residents
Notable changes
- Expands the scope of newborn screening in Oregon.
- Adds screening for five specific genetic diseases not previously included.
Fiscal impact
The bill appropriates $4,000,000 from the General Fund for the biennium beginning July 1, 2025.
Sponsors
Official sponsors from legislative records.
Primary sponsors
Cosponsors
Arguments in favor
Reasons to support this legislation.
Supporters of expanding Oregon's NBS Program advocate for increased funding and expanded conditions to improve early diagnosis and interventions, ultimately enhancing quality of life and preventing premature death. They emphasize the importance of newborn screening for rare conditions, such as Krabbe Disease, which can have devastating health outcomes if left undiagnosed. Proponents highlight the critical role of the program in detecting these conditions and protecting the health of newborns, citing the need for increased funding to keep pace with advancements and ensure equitable access to screening.
Source: Testimony Summaries
Arguments opposed
Reasons to oppose this legislation.
The Oregon Pediatric Society and other opponents of HB 3192 express concerns that the proposed changes to the newborn screening program are not adequately informed by the established consensus process, which they believe is crucial for ensuring the accuracy and effectiveness of the program. They argue that this process, established by the NWRNBS Advisory Board, provides a framework for making evidence-based decisions about newborn screening tests. By deviating from this process, opponents fear that the program may be compromised, potentially leading to misdiagnoses or delayed diagnoses, which could have serious consequences for infants and families.
Source: Testimony Summaries